USA flag logo/image

An Official Website of the United States Government

Identification of a Multi-Analyte Profile for Primary Hyperoxaluria

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93723
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
DK084634
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
RULES-BASED MEDICINE, INC.
3300 Duval Rd AUSTIN, TX 78759-3549
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Identification of a Multi-Analyte Profile for Primary Hyperoxaluria
Agency: HHS
Contract: 1R44DK084634-01
Award Amount: $104,265.00
 

Abstract:

DESCRIPTION (provided by applicant): Primary hyperoxaluria, type 1 (PH1) is a rare, monogenic disorder in which a mutation in the AGXT gene leads to overproduction of oxalate by the liver, resulting in widespread deposition of calcium oxalate in the kidney s and other organs. Unfortunately, PH1 disease progression is not understood. Despite identification of the AGTX mutation, there is little genotype-phenotype correlation in these patients, with kidney stone formation and loss of kidney function proceeding in a seemingly haphazard fashion. Many patients may progress to end- stage kidney disease (ESKD), despite current supportive therapy. An objective diagnostic that accurately detects PH1 and identifies individuals at high risk for rapid progression to ESKD is an unmet clinical need. Clearly, no single molecular marker, or small group of markers, will be able to meet this need. Common proteomic technologies, such as Enzyme-Linked Immunosorbent Assay (ELISA), lack the ability to quantify multiple biomarkers si multaneously. One-at-a-time assessment of each putative biomarker incurs considerable time, cost and sample volume. Newer technologies lack sensitivity, precision and automation. The ability to systematically identify protein profiles, predict risk of clin ical events, evaluate therapeutic response, and define underlying mechanisms is thereby limited severely. Rules-Based Medicine (RBM) resolved these limitations by developing bead-based, multiplexed immunoassays for identifying disease-specific Multi-Analyt e Profiles (MAPs). Exciting preliminary data indicates that MAP technology is well suited for screening large numbers of markers in parallel to identify protein profiles associated with PH1, and may provide insight into the disease course. During Phase I, RBM, and Children's Memorial Hospital (CMH) propose to utilize this quantitative proteomics approach to compare the protein profiles in urine samples obtained from patients diagnosed with PH1 vs. age- and gender-matched control populations. The level and p attern of expression for 201 proteins will be studied. It is expected that the physiological insight obtained from the proposed study may be used to better define the pathological mechanisms associated with PH1. During Phase II, a prospective validation of the MAP identified for PH1 during Phase I efforts will be performed. The sensitivity, specificity,and positive and negative predictive values for each analyte, as well as, the MAP of biomarkers for predicting progression of the disease to ESKD will be det ermined. In addition, a proposed physiological range of MAP analytes for children and adolescents will be developed based on age, and gender for both the normal and PH1 populations. Such range values, typically used for diagnosis and intervention, can be u sed as a reference for future studies and for the development of both a diagnostic test and therapeutic algorithms. The identification of novel biomarker patterns of individuals with PH1, as well as, individuals at high risk for rapid progression to ESKD, will allow for improved management of the condition by objective selection of treatment course or dosage, determining treatment effectiveness, and providing a framework for developing and evaluating new treatments. PUBLIC HEALTH RELEVANCE: Primary hyperoxa luria, type 1 (PH1) is a rare, genetic disorder that leads to widespread deposition of calcium oxalate stones in the kidneys and other organs. Unfortunately, PH1 disease progression is not understood, and many patients may progress to end-stage kidney dise ase, despite therapy. The identification of novel biomarker patterns of individuals with PH1 as well as, individuals at high risk for progression to end-stage kidney disease, will allow for improved management of the condition by objective selection of tre atment course, aiding the determination of treatment dosage and/or effectiveness, and providing a framework for developing and evaluating new treatments.

Principal Investigator:

James P. Mapes
5128358026
JMAPES@RULESBASEDMEDICINE.COM

Business Contact:

Ralph Mcdade
rlmcdade@rulesbasedmedicine.com
Small Business Information at Submission:

RULES-BASED MEDICINE, INC.
RULES-BASED MEDICINE, INC. 3300 DUVAL RD AUSTIN, TX 78759

EIN/Tax ID: 223860791
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No